Europe Virology Market to Grow at a CAGR of 3.4% to reach US$ 1,521.97 million from 2021 to 2028

1. Introduction

1.1 Business Market Insights Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:

4. Europe Virology Market Landscape

4.1 Market Overview

4.2 Porter's Five Forces Analysis

4.2.1 Bargaining Power of Suppliers
4.2.2 Bargaining Power of Buyers
4.2.3 Threat of New Entrants
4.2.4 Competitive Rivalry
4.2.5 Threat of Substitutes

4.3 Ecosystem Analysis

4.3.1 Raw Material Suppliers
4.3.2 Manufacturers
4.3.3 Distributors/Suppliers
4.3.4 End Users

5. Europe Virology Market – Key Market Dynamics

5.1 Growth Drivers

5.1.1
5.1.2 Increasing prevalence of viral infections
5.1.3 Advancements in diagnostic techniques
5.1.4 Rising demand for antiviral drugs
5.1.5 Growing focus on vaccine development
5.1.6 Technological innovations in molecular biology
5.1.7 Expanding healthcare infrastructure in emerging markets
5.1.8 Rising government and private sector funding
5.1.9 Increased awareness and education on viral diseases
5.1.10 Development of personalized medicine
5.1.11 Strong pipeline of antiviral therapeutics
5.1.12 Growing number of biotechnology and pharmaceutical collaborations
5.1.13 Emerging infectious diseases and pandemics
5.1.14 Regulatory support for drug approval processes
5.1.15 Rising adoption of gene therapies
5.1.16 Improved healthcare access and diagnostics in developing regions

5.2 Market Opportunities

5.2.1
5.2.2 Expansion into emerging markets
5.2.3 Development of broad-spectrum antiviral drugs
5.2.4 Advancement in mRNA vaccine technology
5.2.5 Increase in demand for personalized virology treatments
5.2.6 Growth in virology-based diagnostic tools
5.2.7 Opportunity in rare and neglected viral diseases
5.2.8 Collaboration between biotech companies and research institutions
5.2.9 Rise in funding for infectious disease research
5.2.10 Potential in CRISPR-based antiviral therapies
5.2.11 Innovative gene editing applications for viral diseases
5.2.12 Investments in global pandemic preparedness
5.2.13 Advancements in antiviral resistance management
5.2.14 Opportunities in virology-based veterinary medicine
5.2.15 Improved surveillance and monitoring systems for viral outbreaks

5.3 Future Trends

5.3.1
5.3.2 Rise of next-generation antiviral therapies
5.3.3 Integration of AI and machine learning in virology research
5.3.4 Increased focus on viral genomics and personalized medicine
5.3.5 Growth in immunotherapy for viral infections
5.3.6 Expansion of CRISPR-based antiviral interventions
5.3.7 Advancement in viral vector technologies
5.3.8 Proliferation of point-of-care diagnostic solutions
5.3.9 Shift towards preventive virology through vaccines and boosters
5.3.10 Increased adoption of nanotechnology in antiviral drug delivery
5.3.11 Rise of multi-pathogen vaccines
5.3.12 Emergence of synthetic biology in viral research
5.3.13 Growing emphasis on global surveillance networks for emerging viruses
5.3.14 Development of antiviral drugs targeting viral-host interactions
5.3.15 Personalized and precision medicine for viral infections
5.3.16 Growth of telemedicine and digital health in viral disease management

5.4 Impact of Drivers and Restraints

6. Europe Virology Market Regional Analysis

6.1 Europe Virology Market Overview

6.2 Europe Virology Market Revenue 2019-2028 (US$ Million)

6.3 Europe Virology Market Forecast Analysis

7. Europe Virology Market Analysis – by Type

7.1 Diagnostic Test

7.1.1 Overview
7.1.2 Diagnostic Test: Europe Virology Market – Revenue and Forecast to 2031 (US$ Million)

7.2 Viral Infection Controlling Techniques

7.2.1 Overview
7.2.2 Viral Infection Controlling Techniques: Europe Virology Market – Revenue and Forecast to 2031 (US$ Million)

7.3 Antiviral Therapeutics

7.3.1 Overview
7.3.2 Antiviral Therapeutics: Europe Virology Market – Revenue and Forecast to 2031 (US$ Million)

7.4 Interferons

7.4.1 Overview
7.4.2 Interferons: Europe Virology Market – Revenue and Forecast to 2031 (US$ Million)

8. Europe Virology Market Analysis – by Application

8.1 Skin and Soft Tissue Infections

8.1.1 Overview
8.1.2 Skin and Soft Tissue Infections: Europe Virology Market – Revenue and Forecast to 2028 (US$ Million)

8.2 Respiratory Tract Infections

8.2.1 Overview
8.2.2 Respiratory Tract Infections: Europe Virology Market – Revenue and Forecast to 2028 (US$ Million)

8.3 GI Tract Infections

8.3.1 Overview
8.3.2 GI Tract Infections: Europe Virology Market – Revenue and Forecast to 2028 (US$ Million)

8.4 Sexually Transmitted Diseases

8.4.1 Overview
8.4.2 Sexually Transmitted Diseases: Europe Virology Market – Revenue and Forecast to 2028 (US$ Million)

8.5 Urinary Tract Infection

8.5.1 Overview
8.5.2 Urinary Tract Infection: Europe Virology Market – Revenue and Forecast to 2028 (US$ Million)

9. Europe Virology Market Analysis – by End User

9.1 Hospitals

9.1.1 Overview
9.1.2 Urinary Tract Infection: Europe Virology Market – Revenue and Forecast to 2028 (US$ Million)

9.2 Diagnostic Laboratories

9.2.1 Overview
9.2.2 Urinary Tract Infection: Europe Virology Market – Revenue and Forecast to 2028 (US$ Million)

9.3 Pharmaceutical and Biotechnological Companies

9.3.1 Overview
9.3.2 Urinary Tract Infection: Europe Virology Market – Revenue and Forecast to 2028 (US$ Million)

9.4 Research and Academic Institutes

9.4.1 Overview
9.4.2 Urinary Tract Infection: Europe Virology Market – Revenue and Forecast to 2028 (US$ Million)

10. Europe Virology Market – Europe Analysis

10.1 Europe

10.1.1 Europe Virology Market Breakdown, by Key Country, 2022 and 2028 (%)
10.1.1.1 Europe Virology Market – Revenue and Forecast Analysis – by Country
10.1.1.1 UK: Europe Virology Market – Revenue and Forecast to 2028 (US$ Million)

10.1.1.1.1 UK: Europe Virology Market Breakdown, by Type
10.1.1.1.2 UK: Europe Virology Market Breakdown, by Application
10.1.1.1.3 UK: Europe Virology Market Breakdown, by End User

10.1.1.2 Germany: Europe Virology Market – Revenue and Forecast to 2028 (US$ Million)

10.1.1.2.1 Germany: Europe Virology Market Breakdown, by Type
10.1.1.2.2 Germany: Europe Virology Market Breakdown, by Application
10.1.1.2.3 Germany: Europe Virology Market Breakdown, by End User

10.1.1.3 France: Europe Virology Market – Revenue and Forecast to 2028 (US$ Million)

10.1.1.3.1 France: Europe Virology Market Breakdown, by Type
10.1.1.3.2 France: Europe Virology Market Breakdown, by Application
10.1.1.3.3 France: Europe Virology Market Breakdown, by End User

10.1.1.4 Russia: Europe Virology Market – Revenue and Forecast to 2028 (US$ Million)

10.1.1.4.1 Russia: Europe Virology Market Breakdown, by Type
10.1.1.4.2 Russia: Europe Virology Market Breakdown, by Application
10.1.1.4.3 Russia: Europe Virology Market Breakdown, by End User

10.1.1.5 Italy: Europe Virology Market – Revenue and Forecast to 2028 (US$ Million)

10.1.1.5.1 Italy: Europe Virology Market Breakdown, by Type
10.1.1.5.2 Italy: Europe Virology Market Breakdown, by Application
10.1.1.5.3 Italy: Europe Virology Market Breakdown, by End User

10.1.1.6 Rest of Europe: Europe Virology Market – Revenue and Forecast to 2028 (US$ Million)

10.1.1.6.1 Rest of Europe: Europe Virology Market Breakdown, by Type
10.1.1.6.2 Rest of Europe: Europe Virology Market Breakdown, by Application
10.1.1.6.3 Rest of Europe: Europe Virology Market Breakdown, by End User

11. Competitive Landscape

11.1 Heat Map Analysis

11.2 Company Positioning and Concentration

12. Europe Virology Market Industry Landscape

12.1 Overview

12.2 Mergers and Acquisitions

12.3 Agreements, Collaborations, and Joint Ventures

12.4 New Product Launches

12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 Abbott

13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments

13.2 AbbVie Inc.

13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments

13.3 F. Hoffmann-La Roche Ltd.

13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments

13.4 Gilead Sciences, Inc.

13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments

13.5 GlaxoSmithKline Plc

13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments

13.6 Illumina, Inc.

13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments

13.7 Johnson and Johnson Services, Inc.

13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments

13.8 QIAGEN

13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments

13.9 Siemens AG

13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments

13.10 Thermo Fisher Scientific Inc.

13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments

14. Appendix

14.1 About Business Market Insights